RVTY · News · 20260805N

Market Demand Trends

REVVITY, INC. · 2026-08-05 · Importance 36 · Surprise 40

Revvity reported stronger demand for drug-development tools and diagnostic testing products in the second quarter. The Diagnostics segment delivered 11% organic growth, offsetting a decline in the Life Sciences unit. Demand was particularly strong among pharmaceutical and biotechnology customers, with high-content screening orders identified as an additional growth driver. AI-related drug-discovery work contributed incremental demand, although software revenue remained volatile.

Key facts